Based on the encouraging outcomes reported in the literature and our meta-analysis along with a long safety record of use in cancer patients, further randomized controlled trials evaluating the effectiveness of G-CSF in patients with alcoholic hepatitis are required. The gene discussed is CSF3; the disease is alcoholic hepatitis.